Patients with baseline neutropenia may have a relative reduction in N2 neutrophils, potentially lowering VEGF, IL-8, and inflammatory mediators, thereby reducing tumor-promoting inflammation and enhancing chemotherapy-induced tumor cell killing [17]. The gene discussed is VEGFA; the disease is neutropenia.